Imugene’s $20 million boost and cancer trial updates

(7:42)

Imugene (ASX:IMU) | Webinar with Leslie Chong | 07/11/24

(26:56)

Imugene Officially Announce Their HER-Vaxx Trial Results

(8:59)

Imugene forges development path of immunotherapies and cancer-killing virus

(24:2)

Imugene (ASX: IMU) – The ‘Holy Grail’ Of Cancer Treatment…?! | ASX CEO Interview 🚀📈

(20:37)

The First Human Trial Of Virus That Kills Cancer | Imugene Vaxinia Explained

(9:40)

ASX/ausbiz Biotech Unlocked with Imugene CEO Leslie Chong

(18:8)

Imugene's Science Series: PD1-Vaxx (intro)

(37)

Island where people live longer than anyone on earth | 60 Minutes Australia

(12:52)

Interview With The CF33 Oncolytic Virus Inventor - Imugene (IMU)

(20:11)

Imugene featured on Fox Business's 'Trending Today' as a trailblazer in the biotechnology industry.

(4:53)

A Californian Cancer Killer Professor Yuman Fong and his work with Imugene

(26:16)

Imugene (ASX: IMU) - Discussing IMU's 2022 Biotech Opportunity

(20:57)

Virology Lectures 2023 #18: Transformation and oncogenesis

(1:3:39)

Imugene (ASX: IMU) – New Global Partnership Announced For This Leading ASX Biotech

(14:2)

Imugene's Founder and Executive Chairman's keynote speech at Emerging Small Caps Summit 2021

(19:6)

Killing Cancer with Viruses? By Professor Yuman Fong, Inventor of Oncolytic Virus CF33

(20:44)

Imugene's Science Series featuring the Oncolytic Viraltherapy CHECKvacc

(30:2)

Imugene thrilled as first patients dosed in VAXINIA MAST combination study

(5:15)

ROTH - 2023 Healthcare Opportunities Conference: Imugene Limited (ASX:IMU)

(10:44)

'The Why' | Imugene, Developing Cancer Immunotherapies ASX: IMU

(4:51)

Imugene Science Series With Dr Yuman Fong - November 2024

(20:20)

Imugene talks ABL partnership for VAXINIA and $80 million institutional capital raise

(4:50)

Imugene Investor Webinar: MAST Study Update

(27:13)

Imugene Ltd (ASX:IMU) Investor Presentation 2017

(13:15)

Imugene Investor Webinar | Acquisition of License for Azer-Cel Cell Therapy

(33:41)

Imugene HER-Vaxx video ASX: IMU | AN EMERGING LEADER IN CANCER IMMUNO-ONCOLOGY

(4:49)

Imugene (IMU) - ASX Stock Analysis 12th January 2022

(7:1econd)

Azer-cel best in class Allogeneic CAR T cell therapy?

(6:30)